갑상선암 진단 시장 : 기술별, 검체 유형별, 바이오마커 유형별, 용도별, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Thyroid Cancer Diagnostics Market is projected to grow by USD 5.71 billion at a CAGR of 7.35% by 2032.

Thyroid cancer diagnostics are moving from single-test detection toward integrated thyroid nodule evaluation that combines high-resolution ultrasound, fine-needle aspiration cytology, molecular diagnostics, serum biomarkers, and risk-adapted follow-up. This shift is clinically important because WHO/IARC GLOBOCAN 2022 estimated more than 820,000 new thyroid cancer cases worldwide, making thyroid cancer one of the most frequently diagnosed endocrine malignancies.

Demand is being shaped by rising detection of thyroid nodules, broader access to imaging, expanding use of Bethesda System cytopathology, and guideline-driven efforts to distinguish indolent papillary thyroid cancer from aggressive disease. For diagnostic companies, laboratories, hospitals, and imaging networks, the growth opportunity is strongest where tests improve clinical confidence, reduce unnecessary thyroidectomy, and support precision oncology decisions for BRAF, RAS, RET, NTRK, TERT, and other actionable alterations.

Transformative Shifts Reshaping Thyroid Cancer Diagnostics

The thyroid cancer diagnostics landscape is being transformed by three evidence-based shifts: more disciplined ultrasound risk stratification, wider use of molecular testing for indeterminate nodules, and tighter integration between pathology and oncology. Systems such as ACR TI-RADS and ATA ultrasound patterns have made imaging interpretation more standardized, while Bethesda cytology categories continue to guide fine-needle aspiration management.

Molecular diagnostics are changing the value proposition. Rule-out and rule-in assays help clinicians manage Bethesda III and IV nodules, and next-generation sequencing panels can identify mutations and fusions relevant to targeted therapy in advanced thyroid cancer. At the same time, laboratories are adapting to stricter quality, reimbursement, and regulatory expectations, including the EU In Vitro Diagnostic Regulation and heightened scrutiny of laboratory-developed tests in the United States.

Cumulative Impact of Artificial Intelligence on Diagnostic Accuracy

Artificial intelligence is having a cumulative impact across the thyroid cancer diagnostics workflow rather than replacing clinicians outright. In ultrasound imaging, AI models are being developed to classify suspicious thyroid nodules, estimate malignancy risk, support lesion segmentation, and reduce inter-reader variability. In cytopathology, machine learning can assist slide review, cell pattern recognition, and triage of cases that require expert assessment.

The commercial value of AI depends on external validation, explainability, workflow integration, and performance across diverse populations. Peer-reviewed literature shows promising accuracy for thyroid nodule classification, but real-world adoption requires prospective validation, bias monitoring, cybersecurity safeguards, and clear clinical responsibility. The strongest near-term use cases are decision support, quality control, and prioritization of high-risk cases in imaging centers and pathology laboratories.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific represents a high-volume growth arena for thyroid cancer diagnostics due to large patient populations, expanding ultrasound access, and strong diagnostic infrastructure in China, Japan, South Korea, Australia, and increasingly India. North America remains a premium adoption region, supported by advanced endocrine oncology networks, broad molecular testing use, and established clinical guidelines in the United States and Canada.

Europe is defined by guideline consistency, public health systems, and the transition to EU IVDR-compliant diagnostic evidence, creating demand for clinically validated assays and traceable laboratory workflows. Latin America, led by Brazil and Mexico, is expanding access to ultrasound-guided fine-needle aspiration and reference laboratory testing, although reimbursement variability affects molecular test uptake.

The Middle East is investing in tertiary cancer centers, genomic medicine, and private hospital capacity, especially across GCC countries. Africa remains underpenetrated but strategically important, with opportunities tied to ultrasound availability, pathology workforce development, referral networks, and affordable thyroid cancer diagnostic tests that can be deployed across public health systems.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO Markets

ASEAN markets are gaining relevance as urban hospitals expand endocrine imaging and cytology services, with Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines showing different levels of readiness for molecular thyroid cancer diagnostics. The GCC is characterized by high healthcare investment, fast adoption of advanced imaging, and centralized cancer care models that can support genomic testing for thyroid cancer.

The European Union is a major regulatory and evidence-generation hub because EU IVDR is increasing requirements for clinical performance, post-market surveillance, and laboratory quality documentation. BRICS countries collectively represent scale, with China, India, Brazil, Russia, and South Africa offering large patient pools but uneven access to advanced diagnostics.

G7 countries lead in premium diagnostics adoption, clinical guideline development, reimbursement sophistication, and integration of molecular testing into oncology pathways. NATO markets overlap with many high-income healthcare systems and are relevant for supply-chain resilience, cybersecurity standards, laboratory interoperability, and cross-border diagnostic technology procurement.

Key Country Insights for Thyroid Cancer Diagnostics Adoption

The United States leads in molecular thyroid cancer diagnostics, AI-enabled imaging evaluation, and specialized endocrine oncology pathways, while Canada emphasizes evidence-based adoption through provincial health systems. Mexico and Brazil are expanding ultrasound and cytology access, with Brazil offering a major Latin American opportunity for reference laboratory growth and hospital-based molecular testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from established pathology networks, national cancer strategies, and growing use of risk-stratified thyroid nodule management. Russia has strong tertiary care capacity in major cities but faces access variability across regions.

China is scaling thyroid ultrasound, hospital-based pathology, and domestic molecular testing at significant volume. India presents long-term growth driven by population scale, urban specialty care, and private diagnostics expansion, while Japan and South Korea are advanced markets with high imaging penetration and sophisticated cancer centers. Australia combines guideline-led practice with strong pathology standards and digital health adoption.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically validated thyroid nodule diagnostics that reduce unnecessary surgery, improve indeterminate cytology management, and align with ATA, NCCN, ACR TI-RADS, and Bethesda-based workflows. Products should demonstrate utility through real-world evidence, health-economic outcomes, and clear reporting that clinicians can act on.

Organizations should invest in interoperable platforms connecting ultrasound, cytology, molecular results, and longitudinal surveillance data. AI developers must focus on diverse training datasets, transparent performance metrics, prospective validation, and integration into radiology and pathology workflows. Commercial teams should tailor strategies by region, pairing premium genomic testing in mature markets with affordable ultrasound-guided cytology and centralized reference testing in emerging markets.

Research Methodology for Evidence-Based Market Analysis

This executive summary is grounded in a structured research methodology combining secondary research, regulatory review, clinical guideline analysis, and market triangulation. Core evidence sources include WHO/IARC GLOBOCAN cancer statistics, ATA and NCCN thyroid cancer guidance, ACR TI-RADS recommendations, Bethesda System cytopathology standards, peer-reviewed AI and molecular diagnostics literature, and public regulatory information from agencies such as the FDA and European Commission.

Insights were evaluated across test modality, clinical utility, reimbursement environment, regional infrastructure, and adoption barriers. Country and group-level assessments considered healthcare capacity, diagnostic access, oncology referral systems, laboratory maturity, and policy trends. The approach emphasizes verified, data-backed interpretation and avoids unsupported sizing or forecasting claims.

Conclusion: Precision and Workflow Integration Define the Future

Thyroid cancer diagnostics are entering a more precise, connected, and evidence-driven phase. The market is no longer defined only by detecting malignancy; it is increasingly focused on identifying which nodules require intervention, which patients can be monitored safely, and which advanced cancers need targeted therapy selection.

Growth will favor organizations that combine clinical credibility, workflow efficiency, molecular depth, AI-enabled decision support, and regional adaptability. As incidence, imaging utilization, and precision oncology expand, thyroid cancer diagnostics will remain a high-value segment for laboratories, imaging providers, device manufacturers, software developers, and integrated cancer care networks.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Thyroid Cancer Diagnostics Market, by Technology

• 7.1. Immunoassay
  • 7.1.1. Chemiluminescence Immunoassay
  • 7.1.2. ELISA
• 7.2. Immunohistochemistry
• 7.3. Next Generation Sequencing
  • 7.3.1. Targeted Sequencing
  • 7.3.2. Whole Exome Sequencing
  • 7.3.3. Whole Genome Sequencing
• 7.4. Real Time PCR
  • 7.4.1. Digital PCR
  • 7.4.2. qPCR

8. Thyroid Cancer Diagnostics Market, by Sample Type

• 8.1. Blood Sample
• 8.2. Fine Needle Aspiration
• 8.3. Tissue Biopsy

9. Thyroid Cancer Diagnostics Market, by Biomarker Type

• 9.1. Epigenetic Markers
  • 9.1.1. DNA Methylation
  • 9.1.2. miRNA
• 9.2. Genetic Markers
  • 9.2.1. BRAF
  • 9.2.2. RAS
  • 9.2.3. TERT
• 9.3. Protein Markers
  • 9.3.1. Calcitonin
  • 9.3.2. Thyroglobulin

10. Thyroid Cancer Diagnostics Market, by Application

• 10.1. Diagnosis
• 10.2. Prognosis
• 10.3. Recurrence Monitoring
• 10.4. Therapy Monitoring

11. Thyroid Cancer Diagnostics Market, by End User

• 11.1. Academic Research Institutes
  • 11.1.1. Cancer Research Centers
  • 11.1.2. University Laboratories
• 11.2. Ambulatory Care Centers
  • 11.2.1. Imaging Centers
  • 11.2.2. Specialized Clinics
• 11.3. Laboratories
  • 11.3.1. Chain Laboratories
  • 11.3.2. Independent Laboratories
• 11.4. Hospitals
  • 11.4.1. Private Hospitals
  • 11.4.2. Public Hospitals

12. Thyroid Cancer Diagnostics Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Thyroid Cancer Diagnostics Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Thyroid Cancer Diagnostics Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. Becton, Dickinson and Company
• 16.3. bioMerieux S.A.
• 16.4. Bruker Corporation
• 16.5. Canon Medical Systems Corporation
• 16.6. Danaher Corporation
• 16.7. DiaSorin S.p.A.
• 16.8. Exact Sciences Corporation
• 16.9. F. Hoffmann-La Roche Ltd
• 16.10. Foundation Medicine, Inc.
• 16.11. Fujifilm Holdings Corporation
• 16.12. GE HealthCare Technologies Inc.
• 16.13. Guardant Health, Inc.
• 16.14. Hitachi High-Tech Corporation
• 16.15. Hologic, Inc.
• 16.16. Illumina, Inc.
• 16.17. Koninklijke Philips N.V.
• 16.18. Mindray Bio-Medical Electronics Co., Ltd.
• 16.19. Myriad Genetics, Inc.
• 16.20. QIAGEN N.V.
• 16.21. Seegene Inc.
• 16.22. Siemens Healthineers AG
• 16.23. Sysmex Corporation
• 16.24. Thermo Fisher Scientific Inc.